Genetically engineered intracellular single-chain antibodies in gene therapy

Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology

Volumn 22, Issue 2, 2002, Pages 191-211

  Bilbao, Guadalupe ^a   Contreras, Juan Luis ^a,b   Curiel, David T ^a,b  

^a Gene Therapy Center   (United States)

^b Kentucky   (United States)

Author keywords

Colony lift assay; Gene therapy; Heavy chain (VH); Intracellular single chain antibody (scFv); Light chain (VL)

Indexed keywords

COMPLEMENTARY RNA; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MESSENGER RNA; RIBOZYME; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL CELL; ANTIBODY LIBRARY; ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; DNA SYNTHESIS; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GENETIC ENGINEERING; IMMUNOPOTENTIATION; MALIGNANT TRANSFORMATION; NONHUMAN; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ANTIBODIES; GENE THERAPY; GENETIC ENGINEERING; HUMANS; METHODS;

ANIMALIA;

EID: 0036798045     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/MB:22:2:191     Document Type: Article

References (28)

1. Monteith, D. K. and Levin, A. A. (1999) Synthetic oligonucleotides: the development of antisense therapeutics. Toxicol. Pathol. 27, 8-13.
2. Agrawal, S. and Kandimalla, E. R. (2000) Antisense therapeutics: Is it as simple as complementary base recognition? Mol. Med. Today 6, 72-78.
3. Altuvia, S. and Wagner, E. G. (2000) Switching on and off with RNA. Proc. Natl. Acad. Sci. USA 97, 9824-9826.
4. Galderisi, U., Cascino, A., and Giordano, A. (1999) Antisense oligonucleotides as therapeutic agents. J. Cell Physiol. 181, 251-257.
5. Stein, C. A. (2000) Is irrelevant cleavage the price of antisense efficacy? Pharmacel. Ther. 85, 231-236.
6. Stein, C. A. (1999) Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments. Biochim. Biophys. 1489, 45-52.
7. Theuer, C. P. and Pastan I. (1993) Immunotoxins and recombinant toxins in the treatment of solid carcinomas. Am. J. Surg. 166, 284-288.
8. Brinkmann, U., Pai, L. H., and FitzGerald, D. J. (1991) B3-(Fv)-PE38KDEL, a single chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc. Natl. Acad. Sci. USA 88, 8616-8620.
9. Pelegrin, M., Merin, M., Noel, D., and Piechaczyk, M. (1998) Generically engineered antibodies in gene transfer and gene therapy. Hum. Gen. Ther. 9, 2165-2175.
10. Marasco, W. (1997) Intrabodies: turning the humoral immune system outside in for intracellular immunization. Gene Ther. 4, 11-15.
11. Richardson, J. H. and Marasco, W. A. (1995) Intracellular antibodies: development and therapeutic potential. Trends Biotech. 13, 306-310.
12. Baltimore, D. (1988) Intracellular immunization. Nature 335, 395-396.
13. Persic, L., Righi, M., Roberts, A., Hoogenboom, H. R., Cattaneo, A., and Bradbury, A. (1997) Targeting vectors for intracellular immunization. Gene 187, 1-8.
14. Yuen, A. R. and Sikic, B. I. (2000) Clinical studies of antisense therapy in cancer. Front. Biosci. 5, D588-593.
15. Pich, A. and Rancour, T. C. (1999) A role for intracellular immunization in chemosensitization of tumor cells? Gene Ther. 6, 1202-1209.
16. Marasco, W. A., Haseltine, W. A., and Chen, S-Y. (1993) Design, intracellular expression, and activity of human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc. Natl. Acad. Sci. USA 90, 7889-7893.
17. Marasco, W. A., Chen, S-Y., Richardson, J. H., Ramstedt, U., and Jones, S. D. (1998) Intracellular antibodies against HIV-1 envelope proteins for AIDS gene therapy. Hum. Gen. Ther. 8, 1627-1642.
18. Cochet, O., Kenigsburg, M., Delumeau, I., et al. (1998) Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression. Cancer Res. 58, 1170-1176.
19. Deshane, J., Loechel, F., Conry, R. M., Siegal, G. P., King, C. R., and Curiel, D. T. (1994) Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gen. Ther. 1, 332-337.
20. Deshane, J., Siegal, G. P., Alvarez, R. D., et al. (1995) Targeted tumor killing via an intracellular antibody against erbB-2. J. Clin. Invest. 96, 2980-2989.
21. Deshane, J., Grim, J., Loechel, S., Siegal, G. P., Alvarez, R. D., and Curiel, D. T. (1996) Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. Cancer Gene Therapy 3, 89-98.
22. Arafat, W., Gomez-Navarro, J., Xiang, J., Siegal, G. P., Alvarez, R. D., and Curiel, D. T. (2000) Antineoplastic effect of anti-erbB-2 intrabody is not correlated with scFv affinity for its target. Cancer Gene Ther. 7, 1250-1256.
23. Barnes, D. M., Deshane, J., Siegal, G. P., Alvarez, R. D., and Curiel, D. T. (1996) Novel gene therapy strategy to accomplish growth factor modualtion induces enhanced tumor cell chemosensitivity. Clin. Cancer Res. 2, 1089-1095.
24. Wright, M., Grim, J., Kim, M., Strong, T. V., Siegal, G. P., and Curiel, D. T. (1997) An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2. Gene Therapy 4, 317-322.
25. Kim, M., Wright, M., Deshane, J., et al. (1997) A novel gene therapy strategy for elimination of prostate carcinoma cells from human bone marrow. Hum. Gene Ther. 8, 157-170.
26. Alvarez, R. D., Barnes, M. N., Gomez-Navarro, J., et al. (2000) A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin. Cancer Res. 6, 3081-3087.
27. Marks, C. and Marks, J. D. (1996) Phage libraries - a new route to clinically useful antibodies. New Engl. J. Med. 335, 730-733.
28. Rodenburg, C., Mernaugh, R., Bilbao, G., and Khazaeli M. B. (1998) Production of a single cahin anti-CEA antibody from the hybridoma cell line T84. 66 using a modified colony-lift selection procedure to detect antigen-positive scFv bacterial clones. Hybridoma 17, 1-8.